Philips will distribute 4DMedical's noncontrast CT ventilation and perfusion imaging solution CT:VQ to healthcare systems across the U.S. and Canada, 4DMedical announced.
Under the agreement, Philips will provide access to CT:VQ among its established commercial network of hospitals and imaging centers, as well as allocate dedicated sales and clinical specialists, according to the firm.
The partnership builds on growing momentum around CT:VQ following U.S. Food and Drug Administration (FDA) clearance in September 2025, said 4DMedical founder and CEO Andreas Fouras, PhD, in the announcement. The product brings functional lung imaging to sites without nuclear medicine capacity and offers an alternative to traditional nuclear VQ imaging modalities.
CT:VQ converts standard, noncontrast chest CTs into quantitative, lobar ventilation and perfusion maps. Delivered as software‑as‑a‑service (SaaS), the product integrates directly with routine radiology workflows (DICOM-based, PACS reporting) and leverages the U.S. installed base of approximately 14,500 CT scanners, according to 4DMedical.
RSNA 2025 marked the international launch of the Philips collaboration. Since then, the University of Miami has signed on for the clinical use of CT:VQ as of December 10.
In October, Stanford Medicine also signed on to CT:VQ, under a pay-per-scan model. This agreement enables Stanford to access reimbursement pathways, accelerate clinical adoption, and generate real-world evidence. Stanford began 4DMedical's planned rollout strategy across a network of key opinion leader sites at U.S. academic medical centers.
Academic medical centers such as the University of Miami and Stanford will serve as critical reference points for clinical validation, physician education, and broader market adoption of CT:VQ, 4DMedical said.
